[Analysis of Clinical Characteristics and Prognosis of AML Patients with Co-Mutation of CEBPA Gene and GATA2 Gene].

Objective: To analyze the clinical characteristics and prognosis of patients with co-mutation of CEBPA gene and GATA2 gene, so as to facilitate clinicians to formulate more accurate individualized treatment plans for patients.

Methods: A total of 43 acute myeloid leukemia (AML) patients with CEBPA double mutations and CEBPA-bZIP domain mutation admitted to the First Affiliated Hospital of Harbin Medical University from January 2017 to April 2022 were included, and the clinical characteristics and prognosis of patients with GATA2 gene mutation among them were compared and analyzed.

Results: The median age of patients with GATA2 gene mutation was 48.0 years, which was significantly lower than 57.0 years of patients without GATA2 gene mutation (P < 0.05). However, there were no significant differences in sex, white blood cell count, hemoglobin concentration, platelet count, immunophenotype, bone marrow and peripheral blood blast cell ratio and complete remission rate between the two groups (P >0.05). The median overall survival and event-free survival time of patients with GATA2 gene mutation were not reached, while those of patients without GATA2 gene mutation were 14.8 and 8.1 months, respectively (both P < 0.05).

Conclusion: The median age of patients with GATA2 gene mutation is lower than that of patients without GATA2 gene mutation. GATA2 gene mutation further prolongs the survival time of AML patients with CEBPA double mutations and CEBPA-bZIP domain mutation.